<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408907</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Prospective Variation of Cytokine Trends during COVID-19: A Progressive Approach from Disease Onset until Outcome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10578</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910578</ELocationID><Abstract><AbstractText>COVID-19 is characterized by pronounced hypercytokinemia. The cytokine switch, marked by an imbalance between pro-inflammatory and anti-inflammatory cytokines, emerged as a focal point of investigation throughout the COVID-19 pandemic. However, the kinetics and temporal dynamics of cytokine release remain contradictory, making the development of new therapeutics difficult, especially in severe cases. This study collected serum samples from SARS-CoV-2 infected patients at 72 h intervals and monitored them for various cytokines at each timepoint until hospital discharge or death. Cytokine levels were analyzed based on time since symptom onset and patient outcomes. All cytokines studied prospectively were strong predictors of mortality, particularly IL-4 (AUC = 0.98) and IL-1β (AUC = 0.96). First-timepoint evaluations showed elevated cytokine levels in the mortality group (<i>p</i> &lt; 0.001). Interestingly, IFN-γ levels decreased over time in the death group but increased in the survival group. Patients who died exhibited sustained levels of IL-1β and IL-4 and increased IL-6 levels over time. These findings suggest cytokine elevation is crucial in predicting COVID-19 mortality. The dynamic interplay between IFN-γ and IL-4 highlights the balance between Th1/Th2 immune responses and underscores IFN-γ as a powerful indicator of immune dysregulation throughout the infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deus</LastName><ForeName>Marina de Castro</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadotti</LastName><ForeName>Ana Carolina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Erika Sousa</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-5743-5772</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monte Alegre</LastName><ForeName>Júlia Bacarin</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0003-2838-3309</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Spitzenbergen</LastName><ForeName>Beatriz Akemi Kondo</ForeName><Initials>BAK</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Gabriela Bohnen</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tozoni</LastName><ForeName>Sara Soares</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-3573-1738</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocco</LastName><ForeName>Rebecca Benicio</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olandoski</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuon</LastName><ForeName>Felipe Francisco Bondan</ForeName><Initials>FFB</Initials><Identifier Source="ORCID">0000-0003-3471-1786</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinho</LastName><ForeName>Ricardo Aurino</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-3116-4553</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Noronha</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0310-7164</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>Cristina Pellegrino</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0002-5822-6622</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Amaral</LastName><ForeName>Andrea Novais</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-2730-2952</Identifier><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Escola de Medicina, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, PR, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COVID-19 PUC-PR/BRDE</GrantID><Agency>South Region Development Bank, Brazil</Agency><Country /></Grant><Grant><GrantID>COVID-19 internal call</GrantID><Agency>Pontifícia Universidade Católica do Paraná</Agency><Country /></Grant><Grant><GrantID>Scholarships</GrantID><Agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES)</Agency><Country /></Grant><Grant><GrantID>Scholarships</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="Y">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">death</Keyword><Keyword MajorTopicYN="N">hyperinflammation</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408907</ArticleId><ArticleId IdType="pmc">PMC11477561</ArticleId><ArticleId IdType="doi">10.3390/ijms251910578</ArticleId><ArticleId IdType="pii">ijms251910578</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival. Nat. Med. 2020;26:1636–1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulchandani R., Lyngdoh T., Kakkar A.K. Deciphering the COVID-19 Cytokine Storm: Systematic Review and Meta-Analysis. Eur. J. Clin. Investig. 2021;51:e13429. doi: 10.1111/eci.13429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13429</ArticleId><ArticleId IdType="pmc">PMC7646004</ArticleId><ArticleId IdType="pubmed">33058143</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Martin J.C. Pathological Inflammation in Patients with COVID-19: A Key Role for Monocytes and Macrophages. Nat. Rev. Immunol. 2020;20:355–362. doi: 10.1038/s41577-020-0331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., et al. Cytokine Elevation in Severe and Critical COVID-19: A Rapid Systematic Review, Meta-Analysis, and Comparison with Other Inflammatory Syndromes. Lancet Respir. Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30404-5</ArticleId><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., et al. Coronavirus Infections and Immune Responses. J. Med. Virol. 2020;92:424–432. doi: 10.1002/jmv.25685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25685</ArticleId><ArticleId IdType="pmc">PMC7166547</ArticleId><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the Eye of the Cytokine Storm. Microbiol. Mol. Biol. Rev. 2012;76:16–32. doi: 10.1128/MMBR.05015-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Laloraya M. A Cytokine Super Cyclone in COVID-19 Patients with Risk Factors: The Therapeutic Potential of BCG Immunization. Cytokine Growth Factor Rev. 2020;54:32–42. doi: 10.1016/j.cytogfr.2020.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.014</ArticleId><ArticleId IdType="pmc">PMC7328575</ArticleId><ArticleId IdType="pubmed">32747157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Wang T., Cai D., Hu Z., Chen J., Liao H., Zhi L., Wei H., Zhang Z., Qiu Y., et al. Cytokine Storm Intervention in the Early Stages of COVID-19 Pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. doi: 10.1016/j.cytogfr.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7182527</ArticleId><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadotti A.C., de Castro Deus M., Telles J.P., Wind R., Goes M., Garcia Charello Ossoski R., de Padua A.M., de Noronha L., Moreno-Amaral A., Baena C.P., et al. IFN-γ Is an Independent Risk Factor Associated with Mortality in Patients with Moderate and Severe COVID-19 Infection. Virus Res. 2020;289:198171. doi: 10.1016/j.virusres.2020.198171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198171</ArticleId><ArticleId IdType="pmc">PMC7510544</ArticleId><ArticleId IdType="pubmed">32979474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandikattu H.K., Venkateshaiah S.U., Kumar S., Mishra A. IL-15 Immunotherapy Is a Viable Strategy for COVID-19. Cytokine Growth Factor Rev. 2020;54:24–31. doi: 10.1016/j.cytogfr.2020.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7537239</ArticleId><ArticleId IdType="pubmed">32536564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro-Vornhagen A., Gödel P., Subklewe M., Stemmler H.J., Schlößer H.A., Schlaak M., Kochanek M., Böll B., von Bergwelt-Baildon M.S. Cytokine Release Syndrome. J. Immunother. Cancer. 2018;6:56. doi: 10.1186/s40425-018-0343-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-018-0343-9</ArticleId><ArticleId IdType="pmc">PMC6003181</ArticleId><ArticleId IdType="pubmed">29907163</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Louie M.C., Vannella K.M., Wilke C.A., Levine A.M., Moore B.B., Shanley T.P. New Concepts of IL-10-Induced Lung Fibrosis: Fibrocyte Recruitment and M2 Activation in a CCL2/CCR2 Axis. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2011;300:341–353. doi: 10.1152/ajplung.00122.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00122.2010</ArticleId><ArticleId IdType="pmc">PMC3064283</ArticleId><ArticleId IdType="pubmed">21131395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.Y., Qiao K., Liu F., Wu B., Xu X., Jiao G.Q., Lu R.G., Li H.X., Zhao J., Huang J., et al. Lung Transplantation as Therapeutic Option in Acute Respiratory Distress Syndrome for Coronavirus Disease 2019-Related Pulmonary Fibrosis. Chin. Med. J. 2020;133:1390–1396. doi: 10.1097/CM9.0000000000000839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000839</ArticleId><ArticleId IdType="pmc">PMC7339336</ArticleId><ArticleId IdType="pubmed">32251003</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiau M.Y., Chuang P.H., Yang C.P., Hsiao C.W., Chang S.W., Chang K.Y., Liu T.M., Chen H.W., Chuang C.C., Yuan S.Y., et al. Mechanism of Interleukin-4 Reducing Lipid Deposit by Regulating Hormone-Sensitive Lipase. Sci. Rep. 2019;9:11974. doi: 10.1038/s41598-019-47908-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47908-9</ArticleId><ArticleId IdType="pmc">PMC6700157</ArticleId><ArticleId IdType="pubmed">31427606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauridsen C., Matte J.J. Achieving Sustainable Production of Pig Meat. Burleigh Dodds Science Publishing; Sawston, UK: 2017. Recent Advances in Understanding the Role of Vitamins in Pig Nutrition; pp. 165–184.</Citation><ArticleIdList><ArticleId IdType="doi">10.19103/as.2017.0013.09</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M.A., Hural J. Functions of IL-4 and Control of Its Expression. Crit. Rev. Immunol. 2017;37:197–229. doi: 10.1615/CritRevImmunol.v37.i2-6.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevImmunol.v37.i2-6.30</ArticleId><ArticleId IdType="pubmed">29773020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Wu C.A.M., Targ S., Allen C.D.C. IL-21 Is a Broad Negative Regulator of IgE Class Switch Recombination in Mouse and Human B Cells. J. Exp. Med. 2020;217:e20190472. doi: 10.1084/jem.20190472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190472</ArticleId><ArticleId IdType="pmc">PMC7201927</ArticleId><ArticleId IdType="pubmed">32130409</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta Junior J.d.S., Miggiolaro A.F.R.d.S., Nagashima S., de Paula C.B.V., Baena C.P., Scharfstein J., de Noronha L. Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis. Front. Immunol. 2020;11:574862. doi: 10.3389/fimmu.2020.574862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.574862</ArticleId><ArticleId IdType="pmc">PMC7530169</ArticleId><ArticleId IdType="pubmed">33042157</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Escobar L.G., Hoffman K.L., Choi J.J., Borczuk A., Salvatore S., Alvarez-Mulett S.L., Galvan M.D., Zhao Z., Racine-Brzostek S.E., Yang H.S., et al. Cytokine Signatures of End Organ Injury in COVID-19. Sci. Rep. 2021;11:12606. doi: 10.1038/s41598-021-91859-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91859-z</ArticleId><ArticleId IdType="pmc">PMC8206105</ArticleId><ArticleId IdType="pubmed">34131192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirawat R., Saifi M.A., Godugu C. Targeting Inflammatory Cytokine Storm to Fight against COVID-19 Associated Severe Complications. Life Sci. 2021;267:118923. doi: 10.1016/j.lfs.2020.118923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118923</ArticleId><ArticleId IdType="pmc">PMC7831473</ArticleId><ArticleId IdType="pubmed">33358906</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M., Kamimura D., Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity. 2019;50:812–831. doi: 10.1016/j.immuni.2019.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.027</ArticleId><ArticleId IdType="pubmed">30995501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T., Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 2020;52:731–733. doi: 10.1016/j.immuni.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz T.V., Ding Z., Ho P.P., Luo J., Agrawal A.N., Srinagesh H., Axtell R., Zhang H., Platten M., Wyss-Coray T., et al. Angiotensin II Sustains Brain Inflammation in Mice via TGF-β. J. Clin. Investig. 2010;120:2782–2794. doi: 10.1172/JCI41709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI41709</ArticleId><ArticleId IdType="pmc">PMC2912186</ArticleId><ArticleId IdType="pubmed">20628203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehanire T., Ren L., Bond J., Medina M., Li G., Bashirov L., Chen L., Kokosis G., Ibrahim M., Selim A., et al. Angiotensin II Stimulates Canonical TGF-β Signaling Pathway through Angiotensin Type 1 Receptor to Induce Granulation Tissue Contraction. J. Mol. Med. 2014;93:289–302. doi: 10.1007/s00109-014-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-014-1211-9</ArticleId><ArticleId IdType="pmc">PMC4334749</ArticleId><ArticleId IdType="pubmed">25345602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmudpour M., Roozbeh J., Keshavarz M., Farrokhi S. Cytokine COVID-19 Cytokine Storm: The Anger of in Fl Ammation. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155151</ArticleId><ArticleId IdType="pmc">PMC7260598</ArticleId><ArticleId IdType="pubmed">32544563</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D., Parfieniuk-Kowerda A., Rogalska M., Flisiak R. The Role of Th17 Response in COVID-19. Cells. 2021;10:1550. doi: 10.3390/cells10061550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061550</ArticleId><ArticleId IdType="pmc">PMC8235311</ArticleId><ArticleId IdType="pubmed">34205262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Yang X.O. TH17 Responses in Cytokine Storm of COVID-19: An Emerging Target of JAK2 Inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 2020;53:368–370. doi: 10.1016/j.jmii.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacha O., Sallman M.A., Evans S.E. COVID-19: A Case for Inhibiting IL-17? Nat. Rev. Immunol. 2020;20:345–346. doi: 10.1038/s41577-020-0328-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0328-z</ArticleId><ArticleId IdType="pmc">PMC7194244</ArticleId><ArticleId IdType="pubmed">32358580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The Cytokine Storm and COVID-19. J. Med. Virol. 2021;93:250–256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorgham K., Quentric P., Gökkaya M., Marot S., Parizot C., Sauce D., Guihot A., Luyt C.E., Schmidt M., Mayaux J., et al. Distinct Cytokine Profiles Associated with COVID-19 Severity and Mortality. J. Allergy Clin. Immunol. 2021;147:2098–2107. doi: 10.1016/j.jaci.2021.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.03.047</ArticleId><ArticleId IdType="pmc">PMC8061091</ArticleId><ArticleId IdType="pubmed">33894209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinina O., Golovkin A., Zaikova E., Aquino A., Bezrukikh V., Melnik O., Vasilieva E., Karonova T., Kudryavtsev I., Shlyakhto E. Cytokine Storm Signature in Patients with Moderate and Severe COVID-19. Int. J. Mol. Sci. 2022;23:8879. doi: 10.3390/ijms23168879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23168879</ArticleId><ArticleId IdType="pmc">PMC9408700</ArticleId><ArticleId IdType="pubmed">36012146</ArticleId></ArticleIdList></Reference><Reference><Citation>Choreño-Parra J.A., Jiménez-Álvarez L.A., Cruz-Lagunas A., Rodríguez-Reyna T.S., Ramírez-Martínez G., Sandoval-Vega M., Hernández-García D.L., Choreño-Parra E.M., Balderas-Martínez Y.I., Martinez-Sánchez M.E., et al. Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1) Front. Immunol. 2021;12:593595. doi: 10.3389/fimmu.2021.593595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.593595</ArticleId><ArticleId IdType="pmc">PMC8115405</ArticleId><ArticleId IdType="pubmed">33995342</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Kilian C., Turner J.E., Bosurgi L., Roedl K., Bartsch P., Gnirck A.C., Cortesi F., Schultheiß C., Hellmig M., et al. Clonal Expansion and Activation of Tissue-Resident Memory-like Th17 Cells Expressing GM-CSF in the Lungs of Severe COVID-19 Patients. Sci. Immunol. 2021;6:eabf6692. doi: 10.1126/sciimmunol.abf6692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf6692</ArticleId><ArticleId IdType="pmc">PMC8128299</ArticleId><ArticleId IdType="pubmed">33622974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzenberger P., Huang W., Ye P., Oliver P., Manuel M., Zhang Z., Bagby G., Nelson S., Kolls J.K. Requirement of Endogenous Stem Cell Factor and Granulocyte-Colony-Stimulating Factor for IL-17-Mediated Granulopoiesis. J. Immunol. 2000;164:4783–4789. doi: 10.4049/jimmunol.164.9.4783.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.9.4783</ArticleId><ArticleId IdType="pubmed">10779785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Fu B., Zheng X., Wang D., Zhao C., Qi Y., Sun R., Tian Z., Xu X., Wei H. Pathogenic T-Cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients. Natl. Sci. Rev. 2020;7:998–1002. doi: 10.1093/nsr/nwaa041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa041</ArticleId><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology. Semin. Immunopathol. 2017;39:529–539. doi: 10.1007/s00281-017-0629-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozger H.S., Karakus R., Kuscu E.N., Bagriacik U.E., Oruklu N., Yaman M., Turkoglu M., Erbas G., Atak A.Y., Senol E. Serial Measurement of Cytokines Strongly Predict COVID-19 Outcome. PLoS ONE. 2021;16:e0260623. doi: 10.1371/journal.pone.0260623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260623</ArticleId><ArticleId IdType="pmc">PMC8639000</ArticleId><ArticleId IdType="pubmed">34855834</ArticleId></ArticleIdList></Reference><Reference><Citation>Remberto Ramos-González A., Eder Cano-Pérez B.C., Steev Loyola B.C.D., Rita Sierra-Merlano A., Doris Gómez-Camargo B.C. Cytokine Expression and Mortality Risk among COVID-19 Hospitalized Patients over 60 Years of Age in a Referral Hospital in Cartagena, Colombia. Heliyon. 2024;10:e29028. doi: 10.1016/j.heliyon.2024.e29028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e29028</ArticleId><ArticleId IdType="pmc">PMC11004873</ArticleId><ArticleId IdType="pubmed">38601541</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr C., Mang S., Mozafari B., Guenther K., Speer T., Seibert M., Srikakulam S.K., Beisswenger C., Ritzmann F., Keller A., et al. Distinct Patterns of Blood Cytokines beyond a Cytokine Storm Predict Mortality in Covid-19. J. Inflamm. Res. 2021;14:4651–4667. doi: 10.2147/JIR.S320685.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S320685</ArticleId><ArticleId IdType="pmc">PMC8451220</ArticleId><ArticleId IdType="pubmed">34552347</ArticleId></ArticleIdList></Reference><Reference><Citation>Basheer M., Saad E., Kananeh M., Asad L., Khayat O., Badarne A., Abdo Z., Arraf N., Milhem F., Bassal T., et al. Cytokine Patterns in COVID-19 Patients: Which Cytokines Predict Mortality and Which Protect Against? Curr. Issues Mol. Biol. 2022;44:4735–4747. doi: 10.3390/cimb44100323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb44100323</ArticleId><ArticleId IdType="pmc">PMC9600496</ArticleId><ArticleId IdType="pubmed">36286038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S., Zhao Y., Wang F., Chen Y., Kaminga A.C., Xu H. Comorbidities’ Potential Impacts on Severe and Non-Severe Patients with COVID-19: A Systematic Review and Meta-Analysis. Medicine. 2021;100:E24971. doi: 10.1097/MD.0000000000024971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024971</ArticleId><ArticleId IdType="pmc">PMC9281964</ArticleId><ArticleId IdType="pubmed">33761654</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Parra G., Gilbert E.L., Valenzuela-Almada M.O., Vallejo S., Neville M.R., Patel N.J., Cook C., Fu X., Hagi R., McDermott G.C., et al. Risk of Severe COVID-19 Outcomes Associated with Rheumatoid Arthritis and Phenotypic Subgroups: A Retrospective, Comparative, Multicentre Cohort Study. Lancet Rheumatol. 2022;4:e765–e774. doi: 10.1016/S2665-9913(22)00227-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00227-2</ArticleId><ArticleId IdType="pmc">PMC9472567</ArticleId><ArticleId IdType="pubmed">36118532</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudatsir M., Wulandari L., Fajar J.K., Soegiarto G., Ilmawan M., Purnamasari Y., Mahdi B.A., Jayanto G.D., Suhendra S., Setianingsih Y.A., et al. Predictors of COVID-19 Severity: A Systematic Review and Meta-Analysis. F1000Research. 2020;9:1107. doi: 10.12688/f1000research.26186.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.26186.1</ArticleId><ArticleId IdType="pmc">PMC7607482</ArticleId><ArticleId IdType="pubmed">33163160</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D., Blomberg B.B., Paganelli R. Aging, Obesity, and Inflammatory Age-Related Diseases. Front. Immunol. 2017;8:1745. doi: 10.3389/fimmu.2017.01745.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01745</ArticleId><ArticleId IdType="pmc">PMC5725402</ArticleId><ArticleId IdType="pubmed">29270179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinti M., Appay V., Campisi J., Frasca D., Fülöp T., Sauce D., Larbi A., Weinberger B., Cossarizza A. Aging of the Immune System: Focus on Inflammation and Vaccination. Eur. J. Immunol. 2016;46:2286–2301. doi: 10.1002/eji.201546178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201546178</ArticleId><ArticleId IdType="pmc">PMC5156481</ArticleId><ArticleId IdType="pubmed">27595500</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelman L., Pivovarova-Ramich O., Pfeiffer A.F.H., Grune T., Aleksandrova K. Cytokines for Evaluation of Chronic Inflammatory Status in Ageing Research: Reliability and Phenotypic Characterisation. Immun. Ageing. 2019;16:11. doi: 10.1186/s12979-019-0151-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0151-1</ArticleId><ArticleId IdType="pmc">PMC6530020</ArticleId><ArticleId IdType="pubmed">31139232</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin M.N., Siddiqui S.A., Ibrahim M., Hakim M.L., Ahammed M.S., Kabir A., Sultana F. Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease and Cancer. SAGE Open Med. 2020;8:2050312120965752. doi: 10.1177/2050312120965752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050312120965752</ArticleId><ArticleId IdType="pmc">PMC7594225</ArticleId><ArticleId IdType="pubmed">33194199</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Dong M., Pan Q., Wang X., Guo L. Correlation between Changes in Inflammatory Cytokines and the Combination with Hypertension in Patients with Type 2 Diabetes Mellitus. Minerva Endocrinol. 2019;44:252–258. doi: 10.23736/S0391-1977.18.02822-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0391-1977.18.02822-5</ArticleId><ArticleId IdType="pubmed">29687969</ArticleId></ArticleIdList></Reference><Reference><Citation>Caiazzo E., Sharma M., Rezig A.O.M., Morsy M.I., Czesnikiewicz-Guzik M., Ialenti A., Sulicka-Grodzicka J., Pellicori P., Crouch S.H., Schutte A.E., et al. Circulating Cytokines and Risk of Developing Hypertension: A Systematic Review and Meta-Analysis. Pharmacol. Res. 2024;200:107050. doi: 10.1016/j.phrs.2023.107050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2023.107050</ArticleId><ArticleId IdType="pubmed">38159784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidiropoulos P.I., Goulielmos G., Voloudakis G.K., Petraki E., Boumpas D.T. Inflammasomes and Rheumatic Diseases: Evolving Concepts. Ann. Rheum. Dis. 2008;67:1382–1389. doi: 10.1136/ard.2007.078014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.078014</ArticleId><ArticleId IdType="pubmed">17921182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.J., Lin G.J., Chen J.W., Wang K.C., Tien C.H., Hu C.F., Chang C.N., Hsu W.F., Fan H.C., Sytwu H.K. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. Int. J. Mol. Sci. 2019;20:1332. doi: 10.3390/ijms20061332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061332</ArticleId><ArticleId IdType="pmc">PMC6470801</ArticleId><ArticleId IdType="pubmed">30884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G., Qi F., Wang H., Liu Y., Wang X., Zou R., Yuan J., Liao X., Liu Y., Zhang S., et al. The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19. Front. Immunol. 2022;12:816745. doi: 10.3389/fimmu.2021.816745.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.816745</ArticleId><ArticleId IdType="pmc">PMC8795972</ArticleId><ArticleId IdType="pubmed">35095917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X., Pan J., Tao J., Guo D. SARS-CoV Nucleocapsid Protein Antagonizes IFN-β Response by Targeting Initial Step of IFN-β Induction Pathway, and Its C-Terminal Region Is Critical for the Antagonism. Virus Genes. 2011;42:37–45. doi: 10.1007/s11262-010-0544-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-010-0544-x</ArticleId><ArticleId IdType="pmc">PMC7088804</ArticleId><ArticleId IdType="pubmed">20976535</ArticleId></ArticleIdList></Reference><Reference><Citation>Wathelet M.G., Orr M., Frieman M.B., Baric R.S. Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of Nsp1 and Rational Design of an Attenuated Strain. J. Virol. 2007;81:11620–11633. doi: 10.1128/JVI.00702-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00702-07</ArticleId><ArticleId IdType="pmc">PMC2168762</ArticleId><ArticleId IdType="pubmed">17715225</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193. doi: 10.1016/j.chom.2016.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.007</ArticleId><ArticleId IdType="pmc">PMC4752723</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Stetson D.B., Mohrs M., Reinhardt R.L., Baron J.L., Wang Z.E., Gapin L., Kronenberg M., Locksley R.M. Constitutive Cytokine MRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function. J. Exp. Med. 2003;198:1069–1076. doi: 10.1084/jem.20030630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20030630</ArticleId><ArticleId IdType="pmc">PMC2194220</ArticleId><ArticleId IdType="pubmed">14530376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19. Nature. 2020;584:463–469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Rangel F.A., Chávez-Valencia V. High IL-6/IFN-γ Ratio Could Be Associated with Severe Disease in COVID-19 Patients. J. Med. Virol. 2020;92:1789–1790. doi: 10.1002/jmv.25900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25900</ArticleId><ArticleId IdType="pmc">PMC7262117</ArticleId><ArticleId IdType="pubmed">32297995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansoor S., Butt A.R., Bibi A., Mushtaq S., Ullah I., Alshahrani F., Khan A., Mansoor A. Expression of IFN-Gamma Is Significantly Reduced during Severity of Covid-19 Infection in Hospitalized Patients. PLoS ONE. 2023;18:e0291332. doi: 10.1371/journal.pone.0291332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0291332</ArticleId><ArticleId IdType="pmc">PMC10530045</ArticleId><ArticleId IdType="pubmed">37756264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J. Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients. Science. 2020;724:718–724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.T., Linster M., Tan C.W., Le Bert N., Chia W.N., Kunasegaran K., Zhuang Y., Tham C.Y.L., Chia A., Smith G.J.D., et al. Early Induction of Functional SARS-CoV-2-Specific T Cells Associates with Rapid Viral Clearance and Mild Disease in COVID-19 Patients. Cell Rep. 2021;34:108728. doi: 10.1016/j.celrep.2021.108728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108728</ArticleId><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L., Chen Z., Lui G., Wong C.K., Wong W.T., Ng R.W.Y., Tso E.Y.K., Fung K.S.C., Chan V., Yeung A.C.M., et al. Longitudinal Cytokine Profile in Patients with Mild to Critical COVID-19. Front. Immunol. 2021;12:763292. doi: 10.3389/fimmu.2021.763292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.763292</ArticleId><ArticleId IdType="pmc">PMC8685399</ArticleId><ArticleId IdType="pubmed">34938289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yudhawati R., Sakina S., Fitriah M. Interleukin-1β and Interleukin-10 Profiles and Ratio in Serum of COVID-19 Patients and Correlation with COVID-19 Severity: A Time Series Study. Int. J. Gen. Med. 2022;15:8043–8054. doi: 10.2147/IJGM.S381404.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S381404</ArticleId><ArticleId IdType="pmc">PMC9645129</ArticleId><ArticleId IdType="pubmed">36389025</ArticleId></ArticleIdList></Reference><Reference><Citation>Skurk T., Van Harmelen V., Hauner H. Angiotensin II Stimulates the Release of Interleukin-6 and Interleukin-8 from Cultured Human Adipocytes by Activation of NF-ΚB. Arterioscler. Thromb. Vasc. Biol. 2004;24:1199–1203. doi: 10.1161/01.ATV.0000131266.38312.2e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000131266.38312.2e</ArticleId><ArticleId IdType="pubmed">15130920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-ruiz V.J., Illescas-montes R., Puerta-puerta J.M., Ruiz C., Melguizo-rodríguez L. Cytokine and Growth Factor Reviews SARS-CoV-2 Infection: The Role of Cytokines in COVID-19 Disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDiego M.L., Nieto-Torres J.L., Regla-Nava J.A., Jimenez-Guardeño J.M., Fernandez-Delgado R., Fett C., Castaño-Rodriguez C., Perlman S., Enjuanes L. Inhibition of NF-ΚB-Mediated Inflammation in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice Increases Survival. J. Virol. 2014;88:913–924. doi: 10.1128/JVI.02576-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02576-13</ArticleId><ArticleId IdType="pmc">PMC3911641</ArticleId><ArticleId IdType="pubmed">24198408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-Torres J.L., DeDiego M.L., Verdiá-Báguena C., Jimenez-Guardeño J.M., Regla-Nava J.A., Fernandez-Delgado R., Castaño-Rodriguez C., Alcaraz A., Torres J., Aguilella V.M., et al. Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness and Pathogenesis. PLoS Pathog. 2014;10:e1004077. doi: 10.1371/journal.ppat.1004077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004077</ArticleId><ArticleId IdType="pmc">PMC4006877</ArticleId><ArticleId IdType="pubmed">24788150</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu K.L., Yuen K.S., Castano-Rodriguez C., Ye Z.W., Yeung M.L., Fung S.Y., Yuan S., Chan C.P., Yuen K.Y., Enjuanes L., et al. Severe Acute Respiratory Syndrome Coronavirus ORF3a Protein Activates the NLRP3 Inflammasome by Promoting TRAF3-Dependent Ubiquitination of ASC. FASEB J. 2019;33:8865–8877. doi: 10.1096/fj.201802418R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802418R</ArticleId><ArticleId IdType="pmc">PMC6662968</ArticleId><ArticleId IdType="pubmed">31034780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bülow Anderberg S., Luther T., Berglund M., Larsson R., Rubertsson S., Lipcsey M., Larsson A., Frithiof R., Hultström M. Increased Levels of Plasma Cytokines and Correlations to Organ Failure and 30-Day Mortality in Critically Ill Covid-19 Patients. Cytokine. 2021;138:155389. doi: 10.1016/j.cyto.2020.155389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155389</ArticleId><ArticleId IdType="pmc">PMC7833204</ArticleId><ArticleId IdType="pubmed">33348065</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfadda A.A., Siddiqui K., Rafiullah M., Alkhowaiter M., Alotaibi N., Alzahrani M., Binkhamis K., Youssef A.M., Altalhi H., Almaghlouth I., et al. Early Cytokine Signatures of Hospitalized Mild and Severe COVID-19 Patients: A Prospective Observational Study. J. Inflamm. Res. 2023;16:2631–2643. doi: 10.2147/JIR.S408663.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S408663</ArticleId><ArticleId IdType="pmc">PMC10292607</ArticleId><ArticleId IdType="pubmed">37377977</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J.J., Jeon S., Unlu S., Par-Young J., Shin M.S., Kuster J.K., Afinogenova Y., Kang Y., Simonov M., Buller G., et al. A Distinct Association of Inflammatory Molecules with Outcomes of COVID-19 in Younger versus Older Adults. Clin. Immunol. 2021;232:108857. doi: 10.1016/j.clim.2021.108857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108857</ArticleId><ArticleId IdType="pmc">PMC8455237</ArticleId><ArticleId IdType="pubmed">34560283</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Veen R.C., Stohlman S.A. Encephalitogenic Th1 Cells Are Inhibited by Th2 Cells with Related Peptide Specificity: Relative Roles of Interleukin (IL)-4 and IL-10. J. Neuroimmunol. 1993;48:213–220. doi: 10.1016/0165-5728(93)90194-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(93)90194-4</ArticleId><ArticleId IdType="pubmed">8227319</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraille E., Leo O. Revisiting the Th1/Th2 Paradigm. Scand. J. Immunol. 1998;47:213–220. doi: 10.1111/j.1365-3083.1998-47-1.00383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1998-47-1.00383.x</ArticleId><ArticleId IdType="pubmed">9467651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreidler S.M., Muller K.E., Grunwald G.K., Ringham B.M., Coker-Dukowitz Z.T., Sakhadeo U.R., Barón A.E., Glueck D.H. GLIMMPSE: Online Power Computation for Linear Models with and without a Baseline Covariate. J. Stat. Softw. 2013;54:1–26. doi: 10.18637/jss.v054.i10.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v054.i10</ArticleId><ArticleId IdType="pmc">PMC3882200</ArticleId><ArticleId IdType="pubmed">24403868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>